Health Preferences in Transition: Differences from Pandemic to Post-Pandemic in Valuation of COVID-19 and RSV Illness in Children and Adults
Open Access
Abstract
Objective: This study aimed to measure changes in preferences regarding health-related quality of life associated with COVID-19 and RSV illness in children and adults from 2021 (during the COVID-19 pandemic) to 2023 (post-pandemic). Methods: A stated-preference survey elicited time trade-off (TTO) values from US adults in spring 2021 (n = 1014) and summer 2023 (n = 1186). Respondents were asked to indicate how much time they would hypothetically be willing to trade from the end of their life to avoid the effects of varying severities of COVID-19 and RSV illness for: (1) children; (2) parents of an ill child (family spillover); and (3) adults. Attitudes relating to COVID-19 vaccination and data on experience with COVID-19 or RSV illness were also collected. The primary outcome measure was the loss in quality-adjusted life years (QALYs). Changes in preferences over the time period from 2021 to 2023 were evaluated using regression analysis. Results: QALY losses increased with disease severity and were highest for Long COVID. Across all COVID-19 and RSV health states, QALY losses associated with child health states were higher than family spillover or adult health states. In the regression analysis, QALY losses reported in the 2023 survey were significantly lower than 2021 QALY losses for COVID-19, but not RSV. Conclusions: Preferences may change over time in a pandemic context and therefore, economic analyses of pandemic interventions should consider the timeframe of health preference data collection to determine whether they are suitable to include in an economic evaluation. Even with the impacts on health-related quality of life attenuated over time, childhood illnesses still had a measurable impact on caregivers’ quality of life.Keywords
Funding Information
- Centers for Disease Control and Prevention (U01IP001104, 75D30122P15319, DFD—187708, AWD024330)
- Centers for Disease Control and Prevention (U01IP001104, 75D30122P15319, DFD—187708, AWD024330)
- Canadian Institutes of Health Research (U01IP001104, 75D30122P15319, DFD—187708, AWD024330)
- PhRMA Foundation (U01IP001104, 75D30122P15319, DFD—187708, AWD024330)
This publication has 61 references indexed in Scilit:
- Early Correlates of School Readiness Before and During the COVID-19 Pandemic Linking Health and School DataJAMA Pediatrics, 2024
- Proposed subtypes of post‐COVID‐19 syndrome (or long‐COVID) and their respective potential therapiesReviews in Medical Virology, 2021
- Postdischarge symptoms and rehabilitation needs in survivors of COVID‐19 infection: A cross‐sectional evaluationJournal of Medical Virology, 2020
- Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City AreaJAMA, 2020
- Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled studyComplementary Therapies in Clinical Practice, 2020
- The epidemiology and clinical information about COVID-19European Journal of Clinical Microbiology & Infectious Diseases, 2020
- Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going?PharmacoEconomics, 2020
- Overview of Cost-effectiveness AnalysisJAMA, 2019
- Spillover Effects on Caregivers’ and Family Members’ Utility: A Systematic Review of the LiteraturePharmacoEconomics, 2019
- Variation in the Spillover Effects of Illness on Parents, Spouses, and Children of the Chronically IllApplied Health Economics and Health Policy, 2014